Atrial natriuretic peptide (ANP) is a polypeptide which regulates body fluid volume and sodium balance through its potent natriuretic properties (1) . Furthermore, ANP is known to relax vascular smooth muscle cells in the absence of endothelium (2) . It has therefore been speculated that endothelial cells do not have an important role to play in the effect of ANP on vasodilation.
However, recent observations have demonstrated that ANP receptors are present on endothelial cells (3) , and that ANP increases cyclic GMP levels in these cells (4). These observations suggest that ANP influences on endothelial function.
However, this effect has received very little scrutiny, especially concerning the release or synthesis of endothelium-derived vasoactive substances. Endothelin (ET) is a recently discovered 21-amino-acid sequenced polypeptide which is secreted from vascular endothelial cells (5) . This peptide has been reported to have potent vasoconstrictive and proliferative properties on vascular smooth muscle cells (6, 7). Systemic administration of synthetic ET has induced significant biological effects such as an increase of blood pressure, a reduction in cardiac output, and antinatriuresis in humans and animals (8, 9). Furthermore, elevated plasma ET levels have been reported in patients with essential hypertension (10), atherosclerosis (11) and congestive heart failure (12). These findings suggest that ET may contribute to the pathogenesis of these conditions (13). However, the mechanism of ET secretion from vascular endothelial cells is unclear. This study was carried out to clarify the effects of ANP on ET secretion from cultured human vascular endothelial cells.
Materials and Methods

Materials
ANP was purchased from the Peptide Institute (Osaka, Japan), and 8-bromo-cyclic GMP was obtained from Sigma Chemical Co. (St Louis, MO). Modified MCDB 131 (EBM or EGM-UV, Kurabou, Osaka, Japan) was used as the culture medium. together, these findings suggest that the increase in cyclic GMP in the cells may be important for the natriuretic peptide-induced inhibitory action of ET secretion from cultured human endothelial cells. The concentration of ANP added to the medium of the present study was more than 100 times higher than that observed in plasma under various disease conditions (25-27). However, under culture conditions, the peptide in the medium may be degraded during incubation, whereas in vivo, intact ANP is supplied constantly from the heart to the local vascular tissue via blood circulation.
If this ANP-induced inhibitory action of ET secretion occurs in vivo, the pathophysiological implications of this effect in the cardiovascular system must be addressed. Since increased circulating ANP levels have been reported in patients with congestive heart failure (25), hypertension (26) and chronic renal failure (27), ANP may antagonize abnormal vasoconstriction, impaired renal function and exaggerated proliferation of vascular smooth muscle cells possibly caused by ET under these pathological conditions (10, 28, 29).
In conclusion, ANP inhibits accelerated ET secretion from cultured human endothelial cells, probably due to augmentation of intracellular cyclic GMP levels by ANPstimulated guanylate cyclase. 8-bromo-cyclic GMP inhibited ET secretion at 10-3 M (p< 0.01 vs. control).
Data was expressed as mean + SEM.
